EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nirsevimab provides age-specific protection against RSV hospitalisation in the first year of life: a population-level study in Queensland, Australia

Asmaa El-Heneidy, Keith Grimwood, Mohana Rajmokan, Ashish Shrestha, Stephen Lambert, Robert Ware

Communicable Diseases Intelligence · 2026

DOI: 10.33321/cdi.2026.50.066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2026. Verfasst von Asmaa El-Heneidy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Griffith Biostatistics Unit, Griffith University, Gold Coast QLD 4215, Australia; School of Medicine and Dentistry, Griffith University, Gold Coast, …. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hospitalization, Antiviral Agents. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nirsevimab, a long-acting monoclonal antibody with activity against respiratory syncytial virus (RSV), was introduced into the Queensland paediatric RSV prevention program in 2024. Using Queensland Notifiable Conditions Register (NoCS) data, we found that the infant cohort eligible for the nirsevimab program had lower RSV hospitalisation rates than comparable pre-program cohorts. The population-level impact of nirsevimab was greatest during the first month of life (incidence rate ratio [IRR]: 0.22; 95% confidence interval [95% CI]: 0.16–0.31; representing a 78% reduction in hospitalisation rate), with its magnitude gradually declining thereafter until nine months of age (IRR: 0.77; 95% CI: 0.62–0.96; a 23% reduction), following which the impact of nirsevimab on hospitalisation rate, with increasing age of the infant or child, was no longer statistically significant. An interrupted time-series analysis demonstrated an immediate 63% reduction in RSV hospitalisations following nirsevimab’s introduction (IRR: 0.37; 95% CI: 0.23–0.60), showing a substantial population-level impact of the program in Queensland, Australia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsHospitalizationAntiviral AgentsHumansQueenslandInfantFemaleMaleInfant, NewbornRespiratory Syncytial Virus, HumanChild, PreschoolIncidenceAge Factors

Stichwörter der Autor:innen

QueenslandRSVage-specific protectionhospitalisationinterrupted time-seriesnirsevimabpopulation-level impactrespiratory syncytial virusvaccine effectiveness

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Griffith Biostatistics Unit, Griffith University, Gold Coast QLD 4215, Australia; School of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia. a.el-heneidy@griffith.edu.au.
  • School of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia.
  • Public Health Intelligence Branch, Queensland Health, Brisbane QLD 4006, Australia.
  • Child Health Research Centre, The University of Queensland, South Brisbane, QLD 4101, Australia; National Centre for Immunisation Research and Surveillance, Westmead, NSW 2145, Australia.
  • Griffith Biostatistics Unit, Griffith University, Gold Coast QLD 4215, Australia; School of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia; Wesley Research Institute, Brisbane QLD 4066, Aus…

Zitieren

APA

El-Heneidy, A., Grimwood, K., Rajmokan, M., Shrestha, A., Lambert, S., & Ware, R. (2026). Nirsevimab provides age-specific protection against RSV hospitalisation in the first year of life: a population-level study in Queensland, Australia. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2026.50.066

Vancouver

El-Heneidy A, Grimwood K, Rajmokan M, Shrestha A, Lambert S, Ware R. Nirsevimab provides age-specific protection against RSV hospitalisation in the first year of life: a population-level study in Queensland, Australia. Communicable Diseases Intelligence. 2026. doi:10.33321/cdi.2026.50.066

BibTeX
@article{ElHeneidy2026,
  author = {El-Heneidy, Asmaa and Grimwood, Keith and Rajmokan, Mohana and Shrestha, Ashish and Lambert, Stephen and Ware, Robert},
  title = {Nirsevimab provides age-specific protection against RSV hospitalisation in the first year of life: a population-level study in Queensland, Australia},
  journal = {Communicable Diseases Intelligence},
  year = {2026},
  doi = {10.33321/cdi.2026.50.066}
}
Kostenlos starten →